T. Rowe Price Associates
VERV

T. Rowe Price Associates’s Verve Therapeutics VERV Stock Holding History

T. Rowe Price Associates’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,697
Closed -$401K – 3128
2025
Q2 		$401K Buy
35,697
+5,150
+17% +$29.4K ﹤0.01% 2405
2025
Q1 		$140K Buy
30,547
+1,549
+5% +$10.4K ﹤0.01% 2755
2024
Q4 		$164K Sell
28,998
-11,116
-28% -$62.7K ﹤0.01% 2748
2024
Q3 		$195K Buy
40,114
+10,800
+37% +$62.7K ﹤0.01% 2661
2024
Q2 		$144K Buy
29,314
+3,948
+16% +$24.8K ﹤0.01% 2675
2024
Q1 		$337K Buy
25,366
+5,600
+28% +$74.3K ﹤0.01% 2383
2023
Q4 		$276K Buy
19,766
+1,446
+8% +$17.9K ﹤0.01% 2421
2023
Q3 		$243K Buy
18,320
+1,447
+9% +$23.3K ﹤0.01% 2428
2023
Q2 		$317K Buy
16,873
+1,440
+9% +$24K ﹤0.01% 2337
2023
Q1 		$223K Buy
15,433
+628
+4% +$12.3K ﹤0.01% 2472
2022
Q4 		$286K Sell
14,805
-450
-3% -$11.9K ﹤0.01% 2387
2022
Q3 		$525K Buy
+15,255
New +$487K ﹤0.01% 2095
2022
Q1 		– Sell
-5,969
Closed -$220K – 3019
2021
Q4 		$220K Buy
+5,969
New +$251K ﹤0.01% 2721
2021
Q3 		– Sell
-685,000
Closed -$41.3M – 2985
2021
Q2 		$41.3M Buy
+685,000
New +$28.4M ﹤0.01% 1098

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

T. Rowe Price Associates's VERV Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 35,697 shares — an estimated $401K sold.

T. Rowe Price Associates first reported a position in VERV in Q2 2021 and held it in 14 quarters. The position peaked at $41.3M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 35,697 Verve Therapeutics shares in Q3 2025, an estimated $401K.
  • T. Rowe Price Associates first reported a position in Verve Therapeutics in Q2 2021 and held it in 14 quarters.
  • T. Rowe Price Associates's Verve Therapeutics position peaked at $41.3M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.